Fibrovascular organization in the vitreous following laser for ROP: Implications for prognosis

Retina

Volumn 26, Issue 7 SUPPL., 2006, Pages

  Hartnett, M Elizabeth ^a   McColm, Janet R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Fibrovascular organization; Postmenstrual age; Prematurity; Retinal surgery; Retinopathy of prematurity; ROP; Stage 4; Stage 5; Zone

Indexed keywords

ACUTE DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; FEMALE; FISHER EXACT TEST; FOLLOW UP; HUMAN; INFANT; LASER SURGERY; MALE; PROGNOSIS; RANK SUM TEST; RETINA DETACHMENT; RETROLENTAL FIBROPLASIA; STUDENT T TEST; TREATMENT OUTCOME; VITREOUS BODY; VITREOUS DISEASE;

DISEASE PROGRESSION; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HUMANS; INFANT, NEWBORN; LASER COAGULATION; MALE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETINAL DETACHMENT; RETINOPATHY OF PREMATURITY; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VITRECTOMY; VITREOUS BODY;

EID: 33748428192     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iae.0000244286.56133.09     Document Type: Conference Paper

References (14)

1. Coats DK, Miller AM, Brady McCreery KM, et al. Involution of threshold retinopathy of prematurity after diode laser photocoagulation. Ophthalmology 2004;111:1894-1898.
2. Hartnett ME, McColm JR. Retinal features predictive of progression to stage 4 ROP. Retina 2004;24:237-241.
3. Hartnett ME. Features associated with surgical outcome in patients with stages 4 and 5 retinopathy of prematurity. Retina 2003;23:322-329.
4. Fielder AR. Preliminary results of treatment of eyes with high-risk prethreshold retinopathy of prematurity in the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1769-1771.
5. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684-1694.
6. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: Snellen visual acuity and structural outcome at 5 1/2 years after randomization. Arch Ophthalmol 1996;114:417-424.
7. The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol 1984;102:1130-1134.
8. The STOP-ROP Multicenter Study Group. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), a randomized, controlled trial. I: Primary outcomes. Pediatrics 2000;105:295-310.
9. Schaffer DB, Palmer EA, Plotsky DF, et al. Prognostic factors in the natural course of retinopathy of prematurity. Ophthalmology 1993;100:230-237.
10. Trese MT, Capone A. Retinopathy of prematurity: evolution of stages 4 and 5 ROP and management. A. Evolution to retinal detachment and physiologically based management. In: Hartnett ME, Trese MT, Capone A, Keats BJK, Steidl SM, eds. Pediatric Retina. Philadelphia: Lippincott Williams & Wilkins, 2004:411- 416.
11. Hartnett ME, Maguluri S, Thompson HW, et al. Comparison of retinal outcomes after scleral buckle or lens-sparing vitrectomy for stage 4 retinopathy of prematurity. Retina 2004; 24:753-757.
12. Prenner JL, Capone AJ, Trese MT. Visual outcomes after lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Ophthalmology 2004;111:2271-2273.
13. Hubbard GB III, Cherwick DH, Burian G. Lens-sparing vitrectomy for stage 4 retinopathy of prematurity. Ophthalmology 2004;111:2274-2277.
14. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816